Replies to post #6785 on Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

re: analyst coverage, good question and I'm not sure how to get a definitive answer. A reduction in number wouldn't surprise me, though. HALO has managed to severely embarrass the bullish analysts in the past miserable year, so it's possible a few drop out given the uncertainties in the future development, if only to avoid further sullied reputations.

I think a new deal, as you suggest, one which demonstrates a fertile new path (like maybe the "cell therapies" Which to be honest, I have no understanding of right now), will spark more active interest. Otherwise we are stuck in the doldrums.

[Fred Kadiddlehopper]

By the way, (and you probably already know this) Benzinga keeps a list of analyst coverage for HALO so one could cross compare that list with the participants in the call to see any differences. I've no idea if that Benzinga list is current or comprehensive.